Enzon Sells Specialty Pharmaceutical Business To Sigma-tau
Enzon Pharmaceuticals (Enzon) has announced that a special meeting held with its stockholders, has led to the approval for the sale of the company's specialty pharmaceutical business to the Sigma-tau Group.
Enzon's specialty pharmaceutical business includes four marketed products, Oncaspar, Adagen, DepoCyt, and Abelcet, as well as a manufacturing facility in Indianapolis, Indiana.
As previously announced, Enzon entered into a definitive agreement to sell its specialty pharmaceutical business to Sigma-tau for $300m plus, an additional amount of up to $27m based on success milestones.
The company will also receive royalties of 5 to 10% on incremental net sales above a 2009 baseline amount from its four marketed specialty pharmaceutical products through 2014.
The asset sale is expected to be completed later this week.
Enzon Pharmaceuticals is a biopharmaceutical company engaged in the development, manufacturing, commercialization of medicines for patients with cancer and other life-threatening conditions. The company also engages in contract manufacturing for several pharmaceutical companies.
Related Insight
Suppliers Directory
Lonza Custom Manufacturing - Bioresearch Products, Development Services and Manufacturing for Functional and Active Ingredients
Lonza Custom Manufacturing offers the life sciences market a full range of bioresearch products, flexible development services and high-quality manufacturing for functional and active ingredients.
Production & Manufacturing > Fine & Speciality Chemicals > Suppliers
IRIS Biotech - Peptide Synthesis and Pharmaceutical Intermediates
IRIS Biotech is specialised in reagents for peptide synthesis, PEGylation, life science research and biocatalysis.
Production & Manufacturing > Fine & Speciality Chemicals > Suppliers
Chiral Technologies Worldwide - the Global Leader in Enantioselective Chromatography
Chiral Technologies Worldwide, the global leader in enantioselective chromatography, serves pharmaceutical and other life science industries and offers the largest portfolio of chiral stationary phases (CSPs) and analytical and preparative chiral columns for the separation of racemic mixtures into single enantiomers.
Production & Manufacturing > Fine & Speciality Chemicals > Suppliers
Chemonaut - The World of Chemistry at Your Fingertips
Chemonaut provides online compound sourcing and procurement services to life science companies.
Production & Manufacturing > Fine & Speciality Chemicals > Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Fine & Speciality Chemicals Intelligence
PEGylation - The Magic Wand
Published by IRIS Biotech
Production & Manufacturing > Fine & Speciality Chemicals > White Papers
Two novel polysaccharide-based chiral stationary phases
Published by Chiral Technologies
Production & Manufacturing > Fine & Speciality Chemicals > White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.